Item 7.01    Regulation FD Disclosure.

On January 4, 2022, Tonix Pharmaceuticals Holding Corp. (the "Company") issued a press release announcing that it entered into an exclusive option agreement and research collaboration with Kansas State University ("K-State") to develop zinc nanoparticle ("ZNP") mRNA vaccines. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

The Company updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.02 hereto and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.




 Item 8.01. Other Events.

On January 4, 2022, the Company issued a press release announcing that it entered into an exclusive option agreement and research collaboration with K-State to develop ZNP mRNA vaccines that replace the lipid-nanoparticle ("LNP") technology in current COVID-19 vaccines. The new ZNP technology has the potential to confer increased stability to mRNA vaccines over a wide range of temperature and results in more temperature stable mRNA vaccines, including at room temperature. Eliminating the need for LNPs in mRNA vaccines has the potential to speed deployment of new vaccines and make them more available globally without ultra-cold chain supply systems. Under the research agreement, K-State will advance preclinical development of TNX-3700, a new ZNP mRNA vaccine to protect against COVID-19 based on the spike protein from SARS-CoV-2.

The COVID-19 vaccine research under the research agreement will be directed by Robert K. DeLong, Ph.D., associate professor in the Nanotechnology Innovation Center of K-State, together with his colleagues, Dr. Waithaka Mwangi, K-State, Department of Diagnostic Medicine/Pathobiology, and Dr. Juergen Richt, Director of the Center of Excellence for Emerging and Zoonotic Animal Diseases and Director of the NIH COBRE Center on Emerging and Zoonotic Infectious Diseases at K-State.





Forward- Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the intellectual property rights and protections related to TNX-1700, the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.






(d)    Exhibit
         No.                                  Description.
        99.01       Press release of the Company, dated January 4, 2022
        99.02       Corporate Presentation by the Company for January 2022
         104      Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

© Edgar Online, source Glimpses